AdvaMed statement on “Cures 2.0” discussion draft
June 24, 2021
WASHINGTON, D.C. – AdvaMed, the world’s largest trade organization representing medical technology companies, released the following statement from President and CEO Scott Whitaker on the unveiling by U.S. Reps. Diana DeGette (D-Colo.) and Fred Upton (R-Mich.) of a Cures 2.0 discussion draft to update the 21st Century Cures Act:
“The bipartisan 21st Century Cures Act was a great step forward in advancing patient care, and we commend Reps. DeGette and Upton for working in a bipartisan way to ensure that this important law keeps pace with the medical technologies it regulates. We look forward to reviewing the discussion draft closely, but there are a few important proposals that stand out:
“First, we are pleased to see inclusion of the MCIT rule that is so important for seniors on Medicare. Quick coverage under Medicare of ‘breakthrough’ medical technologies that have been deemed safe and effective by the FDA is so crucial for seniors who are suffering and have exhausted most available healthcare options.
“Second, the legislation calls for a $6.5 billion investment in breakthroughs, including diagnostics, devices, and treatments, to increase access to cures and treatments of diseases like cancer, diabetes, and Alzheimer’s, through the creation of a new Advanced Research Projects Agency for Health (ARPA-H).
“Finally, building on the massive growth of telehealth through the Covid-19 crisis, the draft calls for expansion of this critical technology that will save and improve lives, not to mention lower the cost of care to providers, patients, and taxpayers alike.
“We look forward to working with Reps. DeGette and Upton and Congress more broadly on this important proposal to update to the 21st Century Cures law.”
AdvaMed member companies produce the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments. AdvaMed members range from the largest to the smallest medical technology innovators and companies.